Merck & Co. Stock News

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data across multiple hematologic malignancies will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla. from Dec. 6-9. The data shared at the meeting will highlight the company's ongoing commitment to ad...

In volatile markets, Steve Cress recommends a barbell strategy: combining high-yield dividend stocks (MRK, PINE, OMF) with top AI growth stocks (MU, CLS, COMM). Seeking Alpha's quant system outperforms Wall Street by leveraging daily data, sector-relative analysis, and robust risk metrics to identify strong buys.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, has been notified that Tutanota LLC (Tutanota) has commenced an unsolicited “mini-tender” offer, dated November 10, 2025, to purchase up to 1,000,000 shares of Merck common stock at $65.00 per share. The offer price is approximately 24.66% below the closing price of Merck common stock on Novembe...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after cystectomy as adj...

Merck offers strong dividend growth, a robust drug pipeline, and strategic acquisitions, positioning it well beyond Keytruda's patent expiration. MRK's 3.9% dividend yield, low payout ratio, and A+ credit rating support its 14-year dividend growth streak and future income potential. Elevance Health faces near-term headwinds but boasts a large consumer base, efficiency initiatives, and a 13-year...

Merck & Co., Inc. ( MRK ) Jefferies London Healthcare Conference 2025 November 20, 2025 9:30 AM EST Company Participants Peter Dannenbaum - Vice President of Investor Relations Chirfi Guindo - Senior VP & Chief Marketing Officer of Human Health Marjorie C. Green - Senior VP & Head of Late-Stage Oncology - Global Clinical Development Conference Call Participants Akash Tewari - Jefferies LLC, Res...

Screening large-cap Health Care names using earnings yield plus ROTC identified five undervalued blue-chip stocks over $100B market cap. Merck, Bristol-Myers, Gilead, Pfizer, and Amgen screen as the cheapest quality names using a Magic-Formula-style scoring method.

Merck's newest acquisition grants it access to a highly promising medicine. That could help it overcome the challenges its two biggest franchises are facing.